Company news

Eton Pharmaceuticals, Inc. news in 2023

Eton Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 8, 2023

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

October 29, 2023

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

October 3, 2023

Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 22, 2023

Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results

August 9, 2023

Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

July 31, 2023

SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

July 16, 2023

Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection

June 27, 2023

Eton Pharmaceuticals Reports First Quarter 2023 Financial Results

May 10, 2023

Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)

May 9, 2023

Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

May 2, 2023

Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results

March 15, 2023

Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600

March 14, 2023

Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023

March 6, 2023

SWK Holdings Provides Portfolio Update Highlighting Recent Achievements

January 30, 2023

Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection

January 10, 2023

Calls in 2023